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Background: Lithium is an integral drug used in the management of acute mania, unipolar and bipolar depression
and prophylaxis of bipolar disorders. Thyroid abnormalities associated with treatment with lithium have been
widely reported in medical literature to date. These include goitre, hypothyroidism, hyperthyroidism and
autoimmune thyroiditis. This current review explores the varied thyroid abnormalities frequently encountered
among patients on lithium therapy and their management, since lithium is still a fundamental and widely drug
used in psychiatry and Internal Medicine.
Methods: PubMed database and Google scholar were used to search for relevant English language articles relating
to lithium therapy and thyroid abnormalities up to December 2012. The search terms used were lithium treatment,
thyroid abnormalities, thyroid dysfunction, goitre, hypothyroidism, hyperthyroidism, thyrotoxicosis, autoimmune
thyroiditis, lithium toxicity, treatment of affective disorders and depression and side effects of antipsychotic drugs.
Reference lists of the identified articles were further used to identify other studies.
Results: Lithium affects normal thyroid functioning through multiple mechanisms. At the cellular level, it decreases
thyroid hormone synthesis and release. It also decreases peripheral deiodination of tetraiodothyronine (T4) or
thyroxine by decreasing the activity of type I 5’ de-iodinase enzyme. Hypothyroidism and goitre (clinically and/
ultrasonographically detected) are the most prevalent thyroid abnormalities among patients on long term lithium
therapy. Lithium induced hyperthyroidism is very infrequent. Lithium increases the propensity to thyroid
autoimmunity in susceptible individuals due to its effect of augmenting the activity of B lymphocytes and reducing
the ratio of circulating suppressor to cytotoxic T cells.
Conclusions: Thyroid function tests (serum thyroid stimulating hormone, free thyroid hormones-T4 and
triiodothyronine [T3] concentrations and thyroid auto-antibodies) and assessment of thyroid size clinically and by
thyroid ultrasonography ought to be performed among patients initiating lithium therapy at baseline and later
annually. More frequent assessment of thyroid function status and size during the course of therapy is
recommended among middle aged females (≥50 years), patients with a family history of thyroid disease and those
positive for thyroid auto-antibodies (anti-thyroid peroxidase and TSH receptor antibodies).
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Lithium remains an imperative drug in the long term
therapy of bipolar affective disorders. It is also a proven
prophylactic agent against relapses or recurrences of ab-
normal mood episodes in unipolar depression, hypo-
mania and mania [1,2]. It has also been shown to reduce
suicidal risk and short term mortality [3].
Despite its proven efficaciousness, its use is associated
with a myriad of clinical shortcomings. These include: a
narrow therapeutic window hence necessitating regular
monitoring of therapeutic concentrations, cardiac toxicity,
renal tubular dysfunction and endocrinopathies like thy-
roid abnormalities, hyperparathyroidism, transient hyper-
glycemia and nephrogenic diabetes insipidus [2,4-7]. This
review will focus mainly on the effects of lithium on the
normal physiological functioning of the thyroid gland and
the frequently reported thyroid abnormalities associated
with lithium therapy.
General pharmacological features of lithium
Lithium is an alkali metal which is available mainly as lith-
ium carbonate and citrate in immediate- and sustained-
release preparations. It reaches peak plasma concentrations
in 1–2 and 4–5 hours for the immediate and sustained re-
lease formulations respectively with an elimination half life
of 18–36 hours. Its excretion is primarily via the kidneys
and this renal clearance decreases with increasing age [8].
The precise mechanisms by which lithium exerts its
mood stabilising effects are still not very apparent. Its
neurotropic effects are partially explained by the inhibi-
tory effect on the N-methyl D-aspartate receptor that
mediates cellular calcium influx and the suppression of
activation of pro-apoptotic calcium dependent signalling
pathways [9]. Lithium also alters release of neurotrans-
mitters and lessens glutaminergic activity [10].
Effects of lithium on the physiology of the thyroid gland
Multiple effects of lithium on the physiology of the thy-
roid gland have been extensively studied. Lithium has
been shown to be highly concentrated in thyroid cells.
In-vivo and vitro studies in rats have shown that lithium
reduces the uptake of radioiodine into rat thyroid and
salivary glands. In humans, lithium administration may
result in either reduced or increased thyroidal radioio-
dine uptake. Several mechanisms are thought to explain
this dual effect among humans. Low thyroid iodine up-
take could be due to lithium induced iodide retention
and competition for the iodide transport within the thy-
roid gland. An increase in the uptake could be mediated
by the increased secretion of thyroid stimulating hor-
mone (TSH) following lithium induced hypothyroidism
[11].
Another key effect of lithium on thyroid gland func-
tioning occurs at the level of hormone synthesis andrelease. Lithium inhibits synthesis and release of thyroid
hormones. This inhibitory effect is due to the alteration
in the tubulin polymerisation and inhibition of the ac-
tion of TSH on cyclic adenosine mono phosphate (c-
AMP). Lithium also alters the structure of thyroglobulin
thereby affecting protein conformation and function
with subsequent iodotyrosine coupling defects. Lithium
administration is associated with reduced hepatic deiodi-
nation and clearance of free thyroxine (T4). The latter
induces a decrease in the activity of type I 5’ de-iodinase
enzyme [11,12].
Thyroid abnormalities due to lithium therapy
Goitre
The initial inhibition of thyroid hormone synthesis and
release by lithium results into increased TSH concentra-
tions leading to thyroid enlargement. Other mechanisms
proposed to explain thyrocyte proliferation among
patients on lithium therapy are activation of the pro-
proliferative tyrosine kinase and Wnt/beta-catenin sig-
nalling pathways [12-14].
Goitre is the most common clinical finding noted
among patients on lithium therapy. It occurs as a diffuse
and non tender neck swelling. Varying prevalence of
goitre among treated patients has been reported in the
several published studies. This is explained by the differ-
ences in iodine content in the geographical study set-
tings, duration of lithium use and diagnostic study
techniques used [12].
In one early study by Schou et al. among 330 manic-
depressive patients on lithium therapy, clinically detected
goitre was noted among 12 patients, giving a prevalence
of 3.6%. The calculated annual incidence was 4% com-
pared to 1% incidence in a geographically comparable
healthy general population [15]. In another survey by
Bocchetta et al. among 150 outpatients on long term lith-
ium therapy, the prevalence of a visible and / clinically
palpable goitre was 51% [16]. This prevalence reduced
with subsequent follow up [17,18].
Thyroid ultrasonography has been demonstrated to be
a simple, cheap and sensitive method for screening for
goitre and thyroid abnormalities among patients on lith-
ium therapy [19]. In one cross sectional study to deter-
mine the thyroid size and prevalence of goitre among 96
treated patients with affective disorders in Germany,
goitre was reported among 53 (55%) patients on lithium
therapy and 19 (20%) controls (p = 0.003) [20]. In this
study, screening using thyroid ultrasonography identified
more patients with goitre compared to clinical palpation
(N = 53 Vs 19, p < 0.01 compared to N = 24 Vs 12,
p < 0.001 respectively).
Other cross sectional studies have reported similar
findings of higher frequency of goitre of 50% [21]-59%
[22] among lithium treated patients.
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goitre is comparable to that among healthy population.
However, levothyroxine replacement therapy is preferred
more among patients with significant thyroid enlarge-
ment and accompanying compressive symptoms [12].
Hypothyroidism and subclinical hypothyroidism
Hypothyroidism and subclinical hypothyroidism with/
without concomitant goitre is also very prevalent among
patients on lithium therapy in varying reported frequen-
cies ranging from 0% to 52% [16,22-27]. Similarly, dis-
parities in prevalence can be explained by different study
definitions, iodine intake and baseline thyroid auto-
immunity among study subjects [28]. The average dur-
ation of lithium administration prior to the diagnosis of
hypothyroidism is about 18 months, although it can
occur within the first few months [29].
Bocchetta et al. in a study among 150 ambulatory
Sardinian patients on lithium therapy, no cases of
clinical hypothyroidism were documented. Subclinical
hypothyroidism was noted in 19% of the patients.
Among lithium treated patients with positive thyroid
antibodies, the prevalence of subclinical hypothyroidism
increased to 53%. The prevalence of specific antithyroid
antibodies was positively correlated with age and dur-
ation of lithium treatment, and was higher among
women [16].
In another cross sectional study by Kirov et al. among 115
males and 159 females with affective disorders on long term
lithium therapy in the UK, the prevalence of hypothyroidism
was 10.3%. The prevalence was higher among female
patients compared to males (n = 27, 17% Vs n = 4, 3.5% re-
spectively) [30]. A retrospective study of 718 patients on
lithium therapy by Johnson and Eagles reported a compar-
able prevalence of clinical hypothyroidism of 10.4% espe-
cially among female gender (14% Vs 4.5%). The calculated
annual incidence of hypothyroidism in this study was 2.17%
and 0.68% among women and men respectively [26], rela-
tively higher than the reported figures among the commu-
nity in the Whickham survey [31].
The aetiology of lithium associated hypothyroidism
and subclinical hypothyroidism is primarily related to in-
hibition of synthesis and release of thyroid hormones
[12]. Other studies have demonstrated a transient lith-
ium induced increase in titres of thyroid auto-antibodies
(thyroid peroxidase auto-antibodies) present prior to
lithium administration. No lithium induced production
of thyroid auto-antibodies independently is thought to
occur [32,33]. However, some studies have reported con-
trasting results in relation to lithium inducing an in-
crease in the titres of thyroid auto-antibodies. In a cross
sectional study by Baethge et al. among 100 adults with
major affective disorders matched with 100 age-and sex
matched controls with no history of an axis I psychiatricdiagnosis, there was no significant difference in the
prevalence of auto-antibodies against thyroid peroxidase
and thyroglobulin between the patients and the age- and
sex matched healthy controls (0.07% Vs 0.11% and 0.08%
Vs 0.15% respectively). TSH receptor auto-antibodies
were not found in either group [34].
The risk of developing lithium induced hypothyroidism
has been shown to be significantly higher among females,
with increasing age (>50 years), presence of family history of
thyroid disease and thyroid auto-antibodies [28,29,35]. Due
to this high frequency of hypothyroidism, it is clinically
plausible to assess the thyroid function status, thyroid size
and presence of thyroid auto-antibodies in all patients prior
to initiation of lithium therapy and later annually. More fre-
quent assessment of thyroid function tests (at least every 3–
4 months) among middle aged females (>50 years) who are
thyroid auto-antibody positive with family history of thyroid
disease is recommended [29,36]. Levothyroxine replacement
therapy concurrently with lithium administration especially
in the presence of clinically overt hypothyroidism, signifi-
cantly enlarged thyroid glands, subclinical hypothyroidism
and in rapidly cycling or treatment resistant cases is
recommended in the management of lithium induced
hypothyroidism [29].
Hyperthyroidism/thyrotoxicosis
Hyperthyroidism may occur with long term lithium
treatment though to a less extent compared to goitre
and hypothyroidism [23,30,37-40]. In the retrospective
study by Kirov among 209 patients with affective disor-
ders on long term lithium therapy, post treatment thyro-
toxicosis was noted among 2 patients (1 male and 1
female) [23]. Thyrotoxicosis however was noted to occur
earlier in the course of treatment and at a younger age
in the female patient compared to the male patient
(6 years Vs 9 years later and 42 years Vs 50 years
respectively).
In another cross sectional study, 2 (1.8%) of 111 men
who had a mean duration of 80 months of lithium ther-
apy developed thyrotoxicosis, giving an incidence rate of
2.7/1000 survivor years. Only 6 (3.9%) of 152 women
with a mean duration of 73.3 months of lithium therapy
developed thyrotoxicosis, giving an incidence rate of 6.4/
1000 survivor years [24]. In the prospective study by the
same research group among 33 women, only 1 woman
developed hyperthyroidism over the 146 person-years of
follow up [24]. Bocchetta et al. noted only 1 case of
hyperthyroidism among 150 patients on long term lith-
ium therapy during a 15 year follow up equivalent to
976 patient-years, suggesting that lithium induced hyper-
thyroidism is extremely rare [40].
Lithium induced hyperthyroidism is mainly charac-
terised by a transient and painless thyroiditis. Some pub-
lished reports have also shown that lithium is associated
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or non-specific thyroiditis [41,42]. In one single centre
experience among 23 patients with lithium induced
thyrotoxicosis with a median duration of 6 years of
lithium therapy (0.6-25 years), transient thyrotoxicosis
with a painless thyroiditis was noted among 9 (23%)
patients [42].
This transient and painless thyroiditis is thought to be
due to a possible direct toxic effect of lithium on the
thyroid gland [41]. Another mechanism proposed in the
pathogenesis of lithium induced hyperthyroidism/thyro-
toxicosis is related to autoimmunity and auto-antibody
production. In a study by Wilson et al., 20% of lithium
treated patients had thyroid auto-antibodies compared
to 7.5% not on lithium treatment. Lithium treatment in
this study was shown to increase B cell activity and
decreased ratios of suppressor to cytotoxic T cells [43].
This demonstrates that lithium induces thyroid auto-
immunity among susceptible individuals.
Patients with lithium induced hyperthyroidism are best
treated with anti thyroid drugs like carbimazole with/
without steroids. Radioiodine or thyroidectomy should
be reserved for patients with lithium induced Graves’
disease especially in cases of poor compliance to the anti
thyroid drugs. In cases of a toxic nodular goitre with/
without compressive symptoms, a thyroidectomy is
indicated.
In cases of lithium induced thyroiditis, ablative radioio-
dine is not indicated because of its poor uptake. Conserva-
tive management with regular follow up is recommended
in such cases since majority of the patients develop
hypothyroidism subsequently [42].Conclusions
Lithium being an effective and pivotal drug in the manage-
ment of affective disorders, concomitant thyroid dysfunction
remains a pertinent clinical subject to address. Significant
proportions of patients treated with lithium develop clinic-
ally or radiologically confirmed goitre and hypothyroidism.
Lithium increases the risk of thyroid autoimmunity in sus-
ceptible individuals. Lithium induced hyperthyroidism is
infrequent.
Baseline and regular assessment of thyroid function
tests (TSH, free T4); thyroid size using thyroid ultrason-
ography and measurement of titres of auto-antibodies
against thyroid peroxidase is recommended among
patients prior and during lithium therapy.
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